Alpha Tau Medical to Present at Oncology Symposium
Ticker: DRTSW · Form: 6-K · Filed: Dec 6, 2024 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, oncology, press-release
TL;DR
Alpha Tau Medical presenting at a key oncology event on Dec 6th.
AI Summary
Alpha Tau Medical Ltd. announced on December 6, 2024, that it will participate in Ladenburg's Oncology Innovators & Investors Symposium. The company, which develops a novel cancer treatment, will present its latest developments at this event.
Why It Matters
Participation in industry symposiums can increase visibility and attract potential investors or partners, which is crucial for a company in the competitive oncology space.
Risk Assessment
Risk Level: low — This filing is an announcement of participation in an event and does not contain material financial or operational changes.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- Ladenburg (company) — Organizer of the symposium
- December 6, 2024 (date) — Date of press release and announcement
FAQ
What is the purpose of Alpha Tau Medical's participation in the Ladenburg symposium?
Alpha Tau Medical will participate in Ladenburg's Oncology Innovators & Investors Symposium to present its latest developments.
When was the press release regarding the symposium participation issued?
The press release was issued on December 6, 2024.
What form is Alpha Tau Medical filing with the SEC?
Alpha Tau Medical is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Where is Alpha Tau Medical Ltd. headquartered?
Alpha Tau Medical Ltd. is headquartered in Jerusalem, Israel.
What is the Commission File Number for Alpha Tau Medical Ltd.?
The Commission File Number for Alpha Tau Medical Ltd. is 001-41316.
Filing Stats: 300 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-12-06 08:32:18
Filing Documents
- ea0223576-6k_alphatau.htm (6-K) — 19KB
- ea022357601ex99-1_alphatau.htm (EX-99.1) — 6KB
- 0001213900-24-106223.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: December 6, 2024 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3